Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies - Episode 10

A Labeling Indication of SPMS Can Treat More Patients

December 16, 2020

Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.

EP. 1: Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies EP8

EP. 2: Challenges Regarding Coverage for New SPMS Therapies

EP. 3: Evolving Treatment Strategies and Coverage Implications

EP. 4: The Clinical and Economic Burden of SPMS

EP. 5: Determining SPMS as Biological Instead of Classification

EP. 6: Tackling Secondary Progressive Multiple Sclerosis Early on Benefits Patients in a Number of Ways

EP. 7: Biomarkers Used to Detect Secondary Progressive MS Needs Improvement for the Care of Patients

EP. 8: Defining active SPMS

EP. 9: How Patients Present SPMS, How to Act on it

Now Viewing

EP. 10: A Labeling Indication of SPMS Can Treat More Patients

EP. 11: The Struggle of Making an Effective SPMS Treatment Early on

EP. 12: Unmet Needs for All and Most Vulnerable Secondary Progressive MS Patients